These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 19323037

  • 1. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
    Tsuchiya N, Pathipvanich P, Yasuda T, Mukoyama Y, Rojanawiwat A, Matsubayashi T, Saeng-aroon S, Auwanit W, Matsuyama A, Sawanpanyalert P, Ariyoshi K.
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):71-82. PubMed ID: 19323037
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
    Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P.
    J Med Assoc Thai; 2006 Sep; 89(9):1472-8. PubMed ID: 17100387
    [Abstract] [Full Text] [Related]

  • 3. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L, Médecins Sans Frontieres.
    AIDS; 2006 May 12; 20(8):1163-9. PubMed ID: 16691068
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.
    Kiertiburanakul S, Khongnorasat S, Rattanasiri S, Sungkanuparph S.
    J Med Assoc Thai; 2007 Feb 12; 90(2):237-43. PubMed ID: 17375626
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
    Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S.
    J Med Assoc Thai; 2004 Jul 12; 87(7):760-7. PubMed ID: 15521230
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
    Gulick RM, Smeaton LM, D'Aquila RT, Eron JJ, Currier JS, Gerber JG, Acosta E, Sommadossi JP, Tung R, Snyder S, Kuritzkes DR, Murphy RL, AIDS Clinical Trials Group 373 Study Team.
    J Infect Dis; 2001 Mar 01; 183(5):715-21. PubMed ID: 11181147
    [Abstract] [Full Text] [Related]

  • 9. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.
    Clin Infect Dis; 2008 Feb 15; 46(4):611-21. PubMed ID: 18197758
    [Abstract] [Full Text] [Related]

  • 10. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 15; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 11. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D, Apisarnthanarak A, Laowansiri P, Mundy LM.
    HIV Med; 2008 Oct 15; 9(8):636-41. PubMed ID: 18643857
    [Abstract] [Full Text] [Related]

  • 12. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM.
    J Antimicrob Chemother; 2009 Feb 15; 63(2):380-8. PubMed ID: 19036752
    [Abstract] [Full Text] [Related]

  • 13. Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.
    Saeng-aroon S, Tsuchiya N, Auwanit W, Ayuthaya PI, Pathipvanich P, Sawanpanyalert P, Rojanawiwat A, Kannagi M, Ariyoshi K, Sugiura W.
    Antiviral Res; 2010 Jul 15; 87(1):22-9. PubMed ID: 20382184
    [Abstract] [Full Text] [Related]

  • 14. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Mouhari-Touré A, Saka B, Kombat K, Tchangaï-Walla K, Pitche P.
    Bull Soc Pathol Exot; 2008 Dec 15; 101(5):404-6. PubMed ID: 19192611
    [Abstract] [Full Text] [Related]

  • 15. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P.
    Southeast Asian J Trop Med Public Health; 2005 Mar 15; 36(2):362-9. PubMed ID: 15916042
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
    van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, de Baar MP, Schuurman R, Burger DM, Zijlstra EE.
    Trop Med Int Health; 2005 May 15; 10(5):464-70. PubMed ID: 15860093
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
    Laurent C, Kouanfack C, Koulla-Shiro S, Njoume M, Nkene YM, Ciaffi L, Brulet C, Peytavin G, Vergne L, Calmy A, Mpoudi-Ngolé E, Delaporte E.
    AIDS; 2007 Mar 30; 21(6):768-71. PubMed ID: 17413701
    [Abstract] [Full Text] [Related]

  • 18. Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report.
    Pensi T.
    Indian Pediatr; 2007 Jul 30; 44(7):519-21. PubMed ID: 17684304
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
    Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E.
    Lancet; 2007 Jul 30; 364(9428):29-34. PubMed ID: 15234853
    [Abstract] [Full Text] [Related]

  • 20. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
    Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, Audu RA, Araoyinbo ID, Onyewuche JI, Salu OB, Adedoyin JA, Musa AZ.
    J Acquir Immune Defic Syndr; 2005 Sep 01; 40(1):65-9. PubMed ID: 16123684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.